Resveratrol: One molecule, many targets

IUBMB Life

Volumn 60, Issue 5, 2008, Pages 323-332

  Pirola, Luciano ^a,b,c,d,e   Fröjdö, Sara ^a,b,c,d,e  

^a INSERM   (France)

^b CEMAGREF   (France)

^c UNIVERSITÉ DE LYON   (France)

^d UNIVERSITÉ LYON 1   (France)

^e HOSPICES CIVILS DE LYON   (France)

Author keywords

Cyclooxygenases; Insulin sensitivity; Kinases; Lifespan; Resveratrol; Sirtuins

Indexed keywords

ADENYLATE CYCLASE; AROMATASE; DNA DIRECTED DNA POLYMERASE ALPHA; DNA DIRECTED DNA POLYMERASE BETA; I KAPPA B KINASE BETA; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN SYNTHASE; PROTEIN KINASE C; PROTEIN P56; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RESVERATROL; RIBONUCLEOTIDE REDUCTASE; SILENT INFORMATION REGULATOR PROTEIN 2; SIRTUIN; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; STILBENE DERIVATIVE;

BIOLOGICAL ACTIVITY; CAENORHABDITIS ELEGANS; CANCER PREVENTION; CLINICAL TRIAL; COLON CANCER; DROSOPHILA MELANOGASTER; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; ENZYME ACTIVATION; ENZYME INHIBITION; HEART PROTECTION; HUMAN; IC 50; LIFESPAN; NONHUMAN; PROTEIN TARGETING; REVIEW; SINGLE DRUG DOSE; ANIMAL; DRUG ANTAGONISM; METABOLISM;

MAMMALIA; METAZOA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; LIPOXYGENASE; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RIBONUCLEOTIDE REDUCTASES; STILBENES;

EID: 46749136505     PISSN: 15216543     EISSN: 15216551     Source Type: Journal    
DOI: 10.1002/iub.47     Document Type: Review

References (78)

1. Baur, J. A. and Sinclair, D. A. (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov. 5, 493-506.
2. Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S., and Takada, Y. (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24, 2783-2840.
3. Kimura, Y., Okuda, H., and Arichi, S. (1985) Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim. Biophys. Acta 834, 275-278.
4. Jayatilake, G. S., Jayasuriya, H., Lee, E. S., Koonchanok, N. M., Geahlen, R. L., Ashendel, C. L., McLaughlin, J. L., and Chang, C. J. (1993) Kinase inhibitors from Polygonum cuspidatum. J. Nat. Prod. 56, 1805-1810.
5. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275, 218-220.
6. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L., Scherer, B., and Sinclair, D. A. (2003) Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425, 191-196.
7. Wood, J. G., Rogina, B., Lavu, S., Howitz, K., Helfand, S. L., Tatar, M., and Sinclair, D. (2004) Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nature 430, 686-689.
8. Valenzano, D. R., Terzibasi, E., Genade, T., Cattaneo, A., Domenici, L., and Cellerino, A. (2006) Resveratrol prolongs lifespan and retards the onset of age-related markers in a short-lived vertebrate. Curr. Biol. 16, 296-300.
9. Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., Pistell, P. J., Poosala, S., Becker, K. G., Boss, O., Gwinn, D., Wang, M., Ramaswamy, S., Fishbein, K. W., Spencer, R. G., Lakatta, E. G., Le Couteur, D., Shaw, R. J., Navas, P., Puigserver, P., Ingram, D. K., de Cabo, R., and Sinclair, D. A. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature 444, 337-342.
10. Kopp, P. (1998) Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox"? Eur. J. Endocrinol. 138, 619-620.
11. Ungvari, Z., Orosz, Z., Rivera, A., Labinskyy, N., Xiangmin, Z., Olson, S., Podlutsky, A., and Csiszar, A. (2007) Resveratrol increases vascular oxidative stress resistance. Am. J. Physiol. Heart Circ. Physiol. 292, H2417-H2424.
12. Mizutani, K., Ikeda, K., Kawai, Y., and Yamori, Y. (2000) Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. (Tokyo) 46, 78-83.
13. Atten, M. J., Godoy-Romero, E., Attar, B. M., Milson, T., Zopel, M., and Holian, O. (2005) Resveratrol regulates cellular PKC alpha and delta to inhibit growth and induce apoptosis in gastric cancer cells. Invest. New Drugs 23, 111-119. (Pubitemid 40386227)
14. Stewart, J. R. and O'Brian, C. A. (2004) Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKC alpha inhibition. Invest. New Drugs 22, 107-117.
15. El-Mowafy, A. M. and White, R. E. (1999) Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett. 451, 63-67.
16. Kundu, J. K., Shin, Y. K., Kim, S. H., and Surh, Y. J. (2006) Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis 27, 1465-1474.
17. Kotha, A., Sekharam, M., Cilenti, L., Siddiquee, K., Khaled, A., Zervos, A. S., Carter, B., Turkson, J., and Jove, R. (2006) Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 5, 621-629.
18. Fontecave, M., Lepoivre, M., Elleingand, E., Gerez, C., and Guittet, O. (1998) Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421, 277-279. (Pubitemid 28045770)
19. Sun, N. J., Woo, S. H., Cassady, J. M., and Snapka, R. M. (1998) DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J. Nat. Prod. 61, 362-366.
20. Stivala, L. A., Savio, M., Carafoli, F., Perucca, P., Bianchi, L., Maga, G., Forti, L., Pagnoni, U. M., Albini, A., Prosperi, E., and Vannini, V. (2001) Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J. Biol. Chem. 276, 22586-22594.
21. Stewart, J. R., Christman, K. L., and O'Brian, C. A. (2000) Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem. Pharmacol. 60, 1355-1359.
22. Haworth, R. S. and Avkiran, M. (2001) Inhibition of protein kinase D by resveratrol. Biochem. Pharmacol. 62, 1647-1651.
23. Slater, S. J., Seiz, J. L., Cook, A. C., Stagliano, B. A., and Buzas, C. J. (2003) Inhibition of protein kinase C by resveratrol. Biochim. Biophys. Acta 1637, 59-69.
24. Buryanovskyy, L., Fu, Y., Boyd, M., Ma, Y., Hsieh, T. C., Wu, J. M., and Zhang, Z. (2004) Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 43, 11417-11426. (Pubitemid 39186963)
25. Wang, Y. and Leung, L. K. (2007) Pharmacological concentration of resveratrol suppresses aromatase in JEG-3 cells. Toxicol. Lett. 173, 175-180.
26. El-Mowafy, A. M. and Alkhalaf, M. (2003) Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis 24, 869-873.
27. Zang, M., Xu, S., Maitland-Toolan, K. A., Zuccollo, A., Hou, X., Jiang, B., Wierzbicki, M., Verbeuren, T. J., and Cohen, R. A. (2006) Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 55, 2180-2191. (Pubitemid 44743614)
28. Bass, T. M., Weinkove, D., Houthoofd, K., Gems, D., and Partridge, L. (2007) Effects of resveratrol on lifespan in Drosophila melanogaster and Caenorhabditis elegans. Mech. Ageing Dev. 128, 546-552.
29. Parker, J. A., Arango, M., Abderrahmane, S., Lambert, E., Tourette, C., Catoire, H., and Neri, C. (2005) Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 37, 349-350.
30. Bauer, J. H., Goupil, S., Garber, G. B., and Helfand, S. L. (2004) An accelerated assay for the identification of lifespan-extending interventions in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 101, 12980-12985.
31. Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., Geny, B., Laakso, M., Puigserver, P., and Auwerx, J. (2006) Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109-1122.
32. Sun, C., Zhang, F., Ge, X., Yan, T., Chen, X., Shi, X., and Zhai, Q. (2007) SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab. 6, 307-319. (Pubitemid 47468091)
33. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E. Jr., and Walle, U. K. (2004) High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377-1382.
34. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., Booth, T. D., Crowell, J. A., Perloff, M., Gescher, A. J., Steward, W. P., and Brenner, D. E. (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16, 1246-1252.
35. Aggarwal, B. B., Shishodia, S., Sandur, S. K., Pandey, M. K., and Sethi, G. (2006) Inflammation and cancer: how hot is the link? Biochem. Pharmacol. 72, 1605-1621. (Pubitemid 44666739)
36. MacCarrone, M., Lorenzon, T., Guerrieri, P., and Agro, A. F. (1999) Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur. J. Biochem. 265, 27-34.
37. Szewczuk, L. M., Forti, L., Stivala, L. A., and Penning, T. M. (2004) Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents. J. Biol. Chem. 279, 22727-22737.
38. Handler, N., Brunhofer, G., Studenik, C., Leisser, K., Jaeger, W., Parth, S., and Erker, T. (2007) "Bridged" stilbene derivatives as selective cyclooxygenase- 1 inhibitors. Bioorg. Med. Chem. 15, 6109-6118.
39. Subbaramaiah, K., Chung, W. J., Michaluart, P., Telang, N., Tanabe, T., Inoue, H., Jang, M., Pezzuto, J. M., and Dannenberg, A. J. (1998) Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273, 21875-21882.
40. Subbaramaiah, K. and Dannenberg, A. J. (2003) Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24, 96-102.
41. Stewart, J. R., Ward, N. E., Ioannides, C. G., and O'Brian, C. A. (1999) Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38, 13244-13251. (Pubitemid 129515647)
42. Muller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., and Leder, P. (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54, 105-115.
43. Provinciali, M., Re, F., Donnini, A., Orlando, F., Bartozzi, B., Di Stasio, G., and Smorlesi, A. (2005) Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int. J. Cancer 115, 36-45. (Pubitemid 40559666)
44. Duplain, H. (2006) Salvage of ischemic myocardium: a focus on JNK. Adv. Exp. Med. Biol. 588, 157-164.
45. Das, S., Tosaki, A., Bagchi, D., Maulik, N., and Das, D. K. (2006) Potentiation of a survival signal in the ischemic heart by resveratrol through p38 mitogen-activated protein kinase/mitogen- and stress-activated protein kinase 1/cAMP response element-binding protein signaling. J. Pharmacol. Exp. Ther. 317, 980-988.
46. Zhang, J. (2006) Resveratrol inhibits insulin responses in a SirT1-independent pathway. Biochem. J. 397, 519-527. (Pubitemid 44187510)
47. Frojdo, S., Cozzone, D., Vidal, H., and Pirola, L. (2007) Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem. J. 406, 511-518. (Pubitemid 47425457)
48. Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y., and Mills, G. B. (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 4, 988-1004.
49. Sexton, E., Van Themsche, C., LeBlanc, K., Parent, S., Lemoine, P., and Asselin, E. (2006) Resveratrol interferes with AKT activity and triggers apoptosis in human uterine cancer cells. Mol. Cancer 5, 45. (Pubitemid 44712389)
50. Aziz, M. H., Nihal, M., Fu, V. X., Jarrard, D. F., and Ahmad, N. (2006) Resveratrol-caused apoptosis of human prostate carcinoma LNCaP cells is mediated via modulation of phosphatidylinositol 3′-kinase/Akt pathway and Bcl-2 family proteins. Mol. Cancer Ther. 5, 1335-1341.
51. Cecchinato, V., Chiaramonte, R., Nizzardo, M., Cristofaro, B., Basile, A., Sherbet, G. V., and Comi, P. (2007) Resveratrol-induced apoptosis in human T-cell acute lymphoblastic leukaemia MOLT-4 cells. Biochem. Pharmacol. 74, 1568-1574.
52. Karin, M. and Greten, F. R. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5, 749-759.
53. Kundu, J. K., Shin, Y. K., and Surh, Y. J. (2006) Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochem. Pharmacol. 72, 1506-1515.
54. Park, C. E., Kim, M. J., Lee, J. H., Min, B. I., Bae, H., Choe, W., Kim, S. S., and Ha, J. (2007) Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp. Mol. Med. 39, 222-229.
55. Musi, N. and Goodyear, L. J. (2003) AMP-activated protein kinase and muscle glucose uptake. Acta Physiol. Scand. 178, 337-345.
56. Kaeberlein, M., Kirkland, K. T., Fields, S., and Kennedy, B. K. (2005) Genes determining yeast replicative life span in a long-lived genetic background. Mech. Ageing Dev. 126, 491-504.
57. Guarente, L. (2006) Sirtuins as potential targets for metabolic syndrome. Nature 444, 868-874.
58. Yang, T., Fu, M., Pestell, R., and Sauve, A. A. (2006) SIRT1 and endocrine signaling. Trends Endocrinol. Metab. 17, 186-191.
59. Vaziri, H., Dessain, S. K., Ng Eaton, E., Imai, S. I., Frye, R. A., Pandita, T. K., Guarente, L., and Weinberg, R. A. (2001) hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 107, 149-159. (Pubitemid 33035942)
60. Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., Hu, L. S., Cheng, H. L., Jedrychowski, M. P., Gygi, S. P., Sinclair, D. A., Alt, F. W., and Greenberg, M. E. (2004) Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 303, 2011-2015.
61. Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., and Puigserver, P. (2005) Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 434, 113-118. (Pubitemid 40349395)
62. Koubova, J. and Guarente, L. (2003) How does calorie restriction work? Genes Dev. 17, 313-321.
63. Myers, M. G., Jr., Sun, X. J., and White, M. F. (1994) The IRS-1 signaling system. Trends Biochem. Sci. 19, 289-293.
64. Chen, D. and Guarente, L. (2007) SIR2: a potential target for calorie restriction mimetics. Trends Mol. Med. 13, 64-71.
65. Guarente, L. and Picard, F. (2005) Calorie Restriction- the SIR2 Connection. Cell 120, 473-482.
66. Kaeberlein, M., McDonagh, T., Heltweg, B., Hixon, J., Westman, E. A., Caldwell, S. D., Napper, A., Curtis, R., DiStefano, P. S., Fields, S., Bedalov, A., and Kennedy, B. K. (2005) Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem. 280, 17038-17045.
67. Yang, H., Baur, J. A., Chen, A., Miller, C., Adams, J. K., Kisielewski, A., Howitz, K. T., Zipkin, R. E., and Sinclair, D. A. (2007) Design and synthesis of compounds that extend yeast replicative lifespan. Aging Cell 6, 35-43. (Pubitemid 46140138)
68. Borra, M. T., Smith, B. C., and Denu, J. M. (2005) Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 280, 17187-17195.
69. Kaeberlein, M. and Kennedy, B. K. (2007) Does resveratrol activate yeast Sir2 in vivo? Aging Cell 6, 415-416.
70. Saiko, P., Ozsvar-Kozma, M., Bernhaus, A., Jaschke, M., Graser, G., Lackner, A., Grusch, M., Horvath, Z., Madlener, S., Krupitza, G., Handler, N., Erker, T., Jaeger, W., Fritzer-Szekeres, M., and Szekeres, T. (2007) N-hydroxy-N′-(3,4,5-trimethoxyphenyl)-3,4,5-trimethoxy-benzamidine, a novel resveratrol analog, inhibits ribonucleotide reductase in HL-60 human promyelocytic leukemia cells: Synergistic antitumor activity with arabinofuranosylcytosine. Int. J. Oncol. 31, 1261-1266.
71. Srivastava, R. K., Srivastava, A. R., Korsmeyer, S. J., Nesterova, M., Cho-Chung, Y. S., and Longo, D. L. (1998) Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol. Cell Biol. 18, 3509-3517.
72. Long, D. J. II, Iskander, K., Gaikwad, A., Arin, M., Roop, D. R., Knox, R., Barrios, R., and Jaiswal, A. K. (2002) Disruption of dihydronicotinamide riboside:quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity. J. Biol. Chem. 277, 46131-46139.
73. Wang, Z., Hsieh, T. C., Zhang, Z., Ma, Y., and Wu, J. M. (2004) Identification and purification of resveratrol targeting proteins using immobilized resveratrol affinity chromatography. Biochem. Biophys. Res. Commun. 323, 743-749.
74. Wang, Y., Lee, K. W., Chan, F. L., Chen, S., and Leung, L. K. (2006) The red wine polyphenol resveratrol displays bilevel inhibition on aromatase in breast cancer cells. Toxicol. Sci. 92, 71-77.
75. Le Corre, L., Chalabi, N., Delort, L., Bignon, Y. J., and Bernard-Gallon, D. J. (2005) Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol. Nutr. Food Res. 49, 462-471.
76. Matter, W. F., Brown, R. F., and Vlahos, C. J. (1992) The inhibition of phosphatidylinositol 3-kinase by quercetin and analogs. Biochem. Biophys. Res. Commun. 186, 624-631.
77. Sicheri, F., Moarefi, I., and Kuriyan, J. (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609. (Pubitemid 27087567)
78. Walker, E. H., Pacold, M. E., Perisic, O., Stephens, L., Hawkins, P. T., Wymann, M. P., and Williams, R. L. (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell 6, 909-919.